Artielle www.artielle.com
Portland, US · 1 known investors
Artielle Immunotherapeutics develops DRhQ, a therapeutic platform targeting CD74 receptors to treat neuroinflammatory conditions like progressive multiple sclerosis and advanced cancers. The company's approach blocks macrophage migration inhibitory factor signaling to redirect immune cell activity away from CNS injury sites.
AI & Machine LearningBiotechMedical Devices